članak: 1 od 1  
Arhiv za farmaciju
2004, vol. 54, br. 3, str. 137-147
jezik rada: srpski
neklasifikovan
Kombinovana terapija Helicobacter pylori infekcije u Ulkusnoj bolesti
Klinički centar Niš

Sažetak

Helicobacter pylori infekcija (H. pylori) je najrasprostranjenija infekcija na zemljinoj kugli. Maastricht Konsenzus (2000) je u strogo preporučljive indikacije za eradikaciju H. pylori infekcije uvrstio i ulkusnu bolest. Terapija prvog reda u trajanju od 7 dana podrazumeva ordiniranje inhibitora protonske pumpe (omeprazol, lansoprazol, pantoprazol, rabeprazol, esomeprazol) u kombinaciji sa dva od tri antibiotika (klaritromicin, amoksilin ili metronidazol). Ne postoji terapijska opcija koja dovodi do eradikacije H. pylori u svih bolesnika. Nakon bezuspešne terapije prvog reda, ili u bolesnika koji su alergični na penicillin ili kod rezistencije na klaritromicin, sprovodi se terapija drugog reda. Terapija drugog reda traje 7 dana u kombinaciji inhibitora protonske pumpe, tetraciklina, metronidazola i bizmut subcitrata. Nove formulacije (monokapsula) i novi antibiotici i probiotici predstavljaju značajnu alternative standardnoj terapiji.

Ključne reči

Reference

*** (2002) Konsenzus radne grupe za Helicobacter pylori infekciju Jugoslovenskog gastroenterološkog udruženja. u: Osnivački sastanak 25. 04. u Beogradu
Bock, H., Koop, H., Lehn, N., Heep, M. (2000) Rifabutin-based triple therapy after failure of Helicobacter pylori eradication treatment: Preliminary experience. J Clin Gastroenterol, 31(3): 222-5
Cammarota, G., Cianci, R., Cannizzaro, O., Cuoco, L., Pirozzi, G., Gasbarrini, A., Armuzzi, A., Zocco, M.A., Santarelli, L., Arancio, F., Gasbarrini, G. (2000) Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection. Aliment Pharmacol Ther, 14(10): 1339-43
Canducci, F., Armuzzi, A., Cremonini, F., Cammarota, G., Bartolozzi, F., Pola, P., Gasbarrini, G., Gasbarrini, A. (2000) A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates. Aliment Pharmacol Ther, 14(12): 1625-9
Cayla, R. (1996) How to eradicate Helicobacter pylori?. Gastroenterol Clin Biol, 20(1 Pt 2): S119-S130
de Boer, W.A., van Etten, R.J., Schneeberger, P.M., Tytgat, G.N. (2000) A single drug for Helicobacter pylori infection: First results with a new bismuth triple monocapsule. Am J Gastroenterol, 95(3): 641-5
de Boer, W.A., van Etten, R.J., van de Wouw, B.A., Schneeberger, P.M., van Oijen, A.H., Jansen, J.B. (2000) Bismuth-based quadruple therapy for Helicobacter pylori - a single triple capsule plus lansoprazole. Aliment Pharmacol Ther, 14(1): 85-9
European Helicobacter Pylori Study Group (1997) Current European concepts in the management of Helicobacter pylori infection: The Maastricht Consensus Report: European Helicobacter Pylori Study Group. Gut, 41(1): 8-13
Gasbarrini, A., Ojetti, V., Pitocco, D., Armuzzi, A., Silveri, N.G., Pola, P., Ghirlanda, G., Gasbarrini, G. (2000) Efficacy of different Helicobacter pylori eradication regimens in patients affected by insulin-dependent diabetes mellitus. Scand J Gastroenterol, 35(3): 260-3
Gisbert, J.P., Pajares, J.M., Racz, I. (2001) Therapy. Current Opinion in Gastroenterology, 17 (suppl 1): S47-S54
Gisbert, J.P., Gonzalez, L., Calvet, X., Garcia, N., Lopez, T., Roque, M., Gabriel, R., Pajares, J.M. (2000) Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: A meta-analysis of eradication of Helicobacter pylori. Aliment Pharmacol Ther, 14(10): 1319-28
Goh, K.L. (2001) Update of indications for treatment of Helicobacter pylori, including Maastricht 2. Current Opinion in Gastroenterology, 17 (suppl 1): S43-S46
Gotoh, A., Akamatsu, T., Shimizu, T., Shimodaira, K., Kaneko, T., Kiyosawa, K., Ishida, K., Ikeno, T., Sugiyama, A., Kawakami, Y., Ota, H., Katsuyama, T. (2002) Additive effect of pronase on the efficacy of eradication therapy against Helicobacter pylori. Helicobacter, 7(3): 183-91
Graham, D.Y. (1998) Antibiotic resistance in Helicobacter pylori: Implications for therapy. Gastroenterology, 115(5): 1272-7
Hyde, D.K., Buckley, M.J., o'Morain C.A. (1997) Clinical relevance of antimicrobial resistence in Helicobacter pylori infection. u: Moran A.P. i O'Morain C.A. (ur.) Pathogenesis and host response in helicobacter pylori infections, Bad Homburg: Normed -Verlag, str. 230-241
Isomoto, H., Furusu, H., Morikawa, T., Mizuta, Y., Nishiyama, T., Omagari, K., Murase, K., Inoue, K., Murata, I., Kohno, S. (2000) 5-day vs. 7-day triple therapy with rabeprazole, clarithromycin and amoxicillin for Helicobacter pylori eradication. Aliment Pharmacol Ther, 14(12): 1619-23
Kamada, T., Haruma, K., Miyoshi, E., Mihara, M., Kitadai, Y., Yoshihara, M., Sumii, K., Kajiyama, G., Tahara, K., Mukai, T., Kawamura, Y., Hattori, N. (2000) Cetraxate, a mucosal protective agent, combined with omeprazole, amoxycillin, and clarithromycin increases the eradication rate of helicobacter pylori in smokers. Aliment Pharmacol Ther, 14(8): 1089-94
Kihira, K., Satoh, K., Saifuku, K., Kawakami, S., Fukazawa, K., Ishino, Y., Kimura, K., Sugano, K. (2000) Rabeprazole, amoxycillin and low- or high-dose clarithromycin for cure of Helicobacter pylori infection. Aliment Pharmacol Ther, 14(8): 1083-7
Laine, L.L., Hunt, R., Spenard, J. (2000) Bismuth-based Helicobacter pylori (Hp) therapy by a single capsule [Bismuth subcitrate (B) + Metronidazole (M) + tetracycline (T)] + Omeprazole (O) vs O + Amoxicillin (A) + Clarithromycin (C): An interim analysis. Gut, 47 (suppl 1): A100
Malfertheiner, P., Megraud, F., O'Morain, C., Hungin, A.P.S., Jones, R., Axon, A., Graham, D.Y., Tytgat, G., European, H.P.S.G.(EHPSG) (2002) Current concepts in the management of Helicobacter pylori infection: The Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther, 16(2): 167-80
Megraud, F. (1998) Epidemiology and mechanism of antibiotic resistance in Helicobacter pylori. Gastroenterology, 115(5): 1278-82
Milosavljević, T. (2002) Terapija helicobacter pylori infekcije. Acta clinica, vol. 2, br. 1, str. 98-103
Nagorni, A. (2000) Helicobacter pylori na kraju drugog milenijuma. Facta universitatis - series: Medicine and Biology, vol. 7, br. 1, str. 15-25
Ng, E.K., Lam, Y.H., Sung, J.J., Yung, M.Y., To, K.F., Chan, A.C., Lee, D.W., Law, B.K., Lau, J.Y., Ling, T.K., Lau, W.Y., Chung, S.C. (2000) Eradication of Helicobacter pylori prevents recurrence of ulcer after simple closure of duodenal ulcer perforation: Randomized controlled trial. Ann Surg, 231(2): 153-8
Perri, F., Festa, V., Clemente, R., Villani, M.R., Quitadamo, M., Caruso, N., Bergoli, M.L., Andriulli, A. (2001) Randomized study of two 'rescue' therapies for Helicobacter pylori-infected patients after failure of standard triple therapies. Am J Gastroenterol, 96(1): 58-62
Perri, F., Qasim, A., Marras, L., O'Morain, C. (2003) Treatment of Helicobacter pylori infection. Helicobacter, 8 Suppl 1: 53-60
Pilotto, A., o'Morain C. (2000) The 2000 year in Helicobacter pylori Treatment of Helicobacter pylori infection. Current Opinion in Gastroenterology, 16 (suppl. 1): S44- S51
Rigas, B., Feretis, C., Papavassiliou, E.D. (1999) John Lykoudis: An unappreciated discoverer of the cause and treatment of peptic ulcer disease. Lancet, 354(9190): 1634-5
Takagi, A., Koga, Y., Aiba, Y., Kabir, A.M., Watanabe, S., Ohta-Tada, U., Osaki, T., Kamiya, S., Miwa, T. (2000) Plaunotol suppresses interleukin-8 secretion induced by Helicobacter pylori: Therapeutic effect of plaunotol on H. pylori infection. J Gastroenterol Hepatol, 15(4): 374-80
Taskin, V., Gurer, I., Ozyilkan, E., Sare, M., Hilmioglu, F. (2000) Effect of Helicobacter pylori eradication on peptic ulcer disease complicated with outlet obstruction. Helicobacter, 5(1): 38-40
Tulassay, Z., Kryszewski, A., Dite, P., Kleczkowski, D., Rudzinski, J., Bartuzi, Z., Hasselgren, G., Larko, A., Wrangstadh, M. (2001) One week of treatment with esomeprazole-based triple therapy eradicates Helicobacter pylori and heals patients with duodenal ulcer disease. Eur J Gastroenterol Hepatol, 13(12): 1457-65
Tytgat, G.N. (1998) Treatment of peptic ulcer. Digestion, 59(5): 446-52
van der Hulst, R.W., Rauws, E.A., Koycu, B., Keller, J.J., Bruno, M.J., Tijssen, J.G., Tytgat, G.N. (1997) Prevention of ulcer recurrence after eradication of Helicobacter pylori: A prospective long-term follow-up study. Gastroenterology, 113(4): 1082-6
Yoshiyama, H., Nakamura, H., Okamoto, T., Okita, K., Nakazawa, T. (2000) A novel in vitro effect of the mucosal protective agent sofalcone: Inhibition of chemotactic motility in Helicobacter pylori. Aliment Pharmacol Ther, 14 Suppl 1: 230-6
Zanten, S.J.O., Lauritsen, K., Delchier, J.C., Labenz, J., de Argila, C.M., Lind, T., i dr. (2000) 7- day triple therapy with esomeprazole, amoxicillin and clarithromycin for H. pylori (Hp) eradication in duodenal ulcer (DU) disease. Gastroenterology, 118: A503